Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2026-01-12 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the European Commission's approval of their drug 'Teizeild' for the treatment of type 1 diabetes. It details the clinical study results (TN-10), the regulatory approval status, and provides contact information for media and investor relations. As this is a standard corporate announcement regarding product development and regulatory milestones, it falls under the 'Regulatory Filings' category as a general corporate announcement.
2026-01-12 French
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing the European Commission's approval of their drug 'Teizeild' for type 1 diabetes. It details the clinical study results (TN-10), the regulatory approval status, and provides contact information for media and investor relations. As it is a general corporate announcement regarding product development and regulatory milestones that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing.
2026-01-12 English
6-K Filing
Foreign Filer Report
2026-01-09 English
Communiqué de presse : Le médicament Tzield de Sanofi a été accepté pour un examen prioritaire aux États-Unis pour les jeunes enfants atteints de diabète de type 1 de stade 2
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing that the FDA has accepted a supplemental Biologics License Application (sBLA) for their drug Tzield for priority review. It details the clinical context, the regulatory status, and provides contact information for investor and media relations. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains substantive news about drug development progress. Therefore, it is classified as a general regulatory announcement.
2026-01-05 French
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Earnings Release Classification · 95% confidence The document is a press release from Sanofi announcing that the FDA has accepted a supplemental biologic license application (sBLA) for priority review regarding their drug 'Tzield'. This is a standard corporate regulatory announcement regarding product development and regulatory status. Since it does not fit into specific categories like financial reports, shareholder voting, or M&A, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for general regulatory announcements. FY 2026
2026-01-05 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and provides a detailed table of share repurchase transactions conducted by Sanofi between December 29, 2023, and December 31, 2023. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of companies buying back their own shares.
2026-01-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.